STERIS Q1 2027 Earnings Preview: Analysts Eye 7.7% EPS Growth Amid Market Underperformance

Mentor, Ohio-based STERIS plc (STE), valued at $20.6 billion, is set to announce its fiscal Q1 2027 earnings soon. Analysts project a diluted EPS of $2.52, reflecting a 7.7% year-over-year increase from $2.34 in the prior-year period. The company has beaten or matched consensus estimates in three of the last four quarters, though it missed once. For the full year, EPS of $11.18 is anticipated, up 9.9% from $10.17 in fiscal 2026, with a projected 7.7% YoY rise to $12.04 in fiscal 2028. STE shares have underperformed the S&P 500 Index's 20.3% gains over 52 weeks, declining 2.9%, while lagging the State Street Health Care Select Sector SPDR ETF (XLV)'s 20.5% returns. Following its May 11 Q4 report, STE closed 2.7% lower, with revenue at $1.6 billion (+7.3% YoY) and adjusted EPS of $2.83 (+3.3% YoY). Analyst sentiment remains cautiously optimistic, with a "Moderate Buy" consensus; five of eight analysts rate it "Strong Buy," three "Hold," and an average price target of $254.43 implying 15.1% upside potential.